GK and type 2 diabetes mellitus: Dorzagliatin is currently in clinical trials for the treatment of T2DM due to its novel dual GK activation in the pancreas and liver [17], and preclinical studies have shown that dorzagliatin has a good pharmacokinetic profile in healthy individuals [18] and good efficacy and safety in the treatment of T2DM [17].